Regeneron Faces Securities Class Action Over Failed Drug Trial
Investors who purchased Regeneron Pharmaceuticals stock between August 1, 2025, and May 15, 2026, are facing a legal deadline of September 14, 2026, to join a class action lawsuit. The litigation targets alleged violations of the Securities Exchange Act following the disclosure of disappointing clinical trial results.


















